<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fphar.2017.00482</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>Perilla frutescens</italic> Extracts Protects against Dextran Sulfate Sodium-Induced Murine Colitis: NF-&#x03BA;B, STAT3, and Nrf2 as Putative Targets</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Park</surname> <given-names>Deung Dae</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/420893/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Yum</surname> <given-names>Hye-Won</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/451404/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhong</surname> <given-names>Xiancai</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/453373/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname> <given-names>Seung Hyeon</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/462937/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname> <given-names>Seong Hoon</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/447121/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname> <given-names>Do-Hee</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname> <given-names>Su-Jung</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/421010/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Na</surname> <given-names>Hye-Kyung</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sato</surname> <given-names>Atsuya</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Miura</surname> <given-names>Takehito</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Surh</surname> <given-names>Young-Joon</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/236226/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Tumor Microenvironment Global Core Research Center, Seoul National University</institution> <country>Seoul, South Korea</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Molecular Medicine and Biopharmaceutical Sciences, College of Pharmacy, Seoul National University</institution> <country>Seoul, South Korea</country></aff>
<aff id="aff3"><sup>3</sup><institution>Cancer Research Institute, Seoul National University</institution> <country>Seoul, South Korea</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Food Science and Biotechnology, College of Knowledge-Based Services Engineering, Sungshin Women&#x2019;s University</institution> <country>Seoul, South Korea</country></aff>
<aff id="aff5"><sup>5</sup><institution>Amino Up Chemical Co., Ltd.</institution> <country>Sapporo, Japan</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: <italic>jianbo Xiao, University of Macau, China</italic></p></fn>
<fn fn-type="edited-by"><p>Reviewed by: <italic>Kenji Sato, Kyoto University, Japan; Lei Chen, Fujian Agriculture and Forestry University, China</italic></p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x002A;Correspondence: <italic>Young-Joon Surh, <email>surh@snu.ac.kr</email>; <email>surhyoungjoon@yahoo.co.kr</email></italic></p></fn>
<fn fn-type="other" id="fn002"><p><sup>&#x2020;</sup><italic>These authors have contributed equally to this work.</italic></p></fn>
<fn fn-type="other" id="fn003"><p>This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology</p></fn></author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>08</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>482</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>03</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>07</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2017 Park, Yum, Zhong, Kim, Kim, Kim, Kim, Na, Sato, Miura and Surh.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Park, Yum, Zhong, Kim, Kim, Kim, Kim, Na, Sato, Miura and Surh</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p><italic>Perilla frutescens</italic> is a culinary and medicinal herb which has a strong anti-inflammatory and antioxidative effects. In the present study, we investigated the effects of <italic>Perilla frutescens</italic> extract (PE) against dextran sulfate sodium (DSS)-induced mouse colitis, an animal model that mimics human inflammatory bowel disease (IBD). Five-week-old male ICR mice were treated with a daily dose of PE (20 or 100 mg/kg, <italic>p.o.</italic>) for 1 week, followed by administration of 3% DSS in double distilled drinking water and PE by gavage for another week. DSS-induced colitis was characterized by body weight loss, colon length shortening, diarrhea and bloody stool, and these symptoms were significantly ameliorated by PE treatment. PE administration suppressed DSS-induced expression of proinflammatory enzymes, including cyclooxygenase-2 and inducible nitric oxide synthase as well as cyclin D1, in a dose-dependent fashion. Nuclear factor-kappa B (NF-&#x03BA;B) and signal transducer and activator of transcription 3 (STAT3) are major transcriptional regulators of inflammatory signaling. PE administration significantly inhibited the activation of both NF-&#x03BA;B and STAT3 induced by DSS, while it elevated the accumulation of Nrf2 and heme oxygenase-1 in the colon. In another experiment, treatment of CCD841CoN human normal colon epithelial cells with PE (10 mg/ml) resulted in the attenuation of the tumor necrosis factor-&#x03B1;-induced expression/activation of mediators of proinflammatory signaling. The above results indicate that PE has a preventive potential for use in the management of IBD.</p>
</abstract>
<kwd-group>
<kwd>colitis</kwd>
<kwd>dextran sulfate sodium</kwd>
<kwd>inflammatory bowel disease</kwd>
<kwd><italic>Perilla frutescens</italic></kwd>
<kwd>NF-&#x03BA;B</kwd>
<kwd>STAT3</kwd>
</kwd-group>
<counts>
<fig-count count="9"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="45"/>
<page-count count="14"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec><title>Introduction</title>
<p>Colorectal cancer has become prevalent not only in Western societies, but also in other parts of the world (<xref ref-type="bibr" rid="B33">Torre et al., 2015</xref>). Patients with inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn&#x2019;s disease, have been at increased risk for developing colorectal cancer (<xref ref-type="bibr" rid="B22">Kim and Chang, 2014</xref>). IBD is an illness in which colon becomes inflamed and caused by genetic problems, immune disorders, environmental conditions, and infections (<xref ref-type="bibr" rid="B4">Ananthakrishnan, 2015</xref>). Multiple mechanisms, including overproduction of reactive oxygen species (ROS) in the inflamed colonic mucosa, immune response by mucosal inflammatory mediators, and altered intestinal microbiota, are speculated to be involved the pathogenesis of IBD.</p>
<p>Elevated expression and/or activity of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) have been associated with IBD and inflammation-associated carcinogenesis. COX-2 catalyzes the breakdown of arachidonic acid, thereby producing prostaglandin E<sub>2</sub>, a lipid mediator of inflammation, which promotes tumorigenesis (<xref ref-type="bibr" rid="B37">Wang and Dubois, 2010</xref>). iNOS is responsible for production of nitric oxide (NO) derived from <sc>L</sc>-arginine. Excessive formation of NO causes nitrosative stress which leads to cell cycle disorders, apoptotic cell death, and DNA damage (<xref ref-type="bibr" rid="B3">Aktan, 2004</xref>).</p>
<p>Nuclear factor-kappa B (NF-&#x03BA;B) and signal transducer and activator of transcription 3 (STAT3) are representative transcription factors that play prominent roles in inflammatory signaling (<xref ref-type="bibr" rid="B34">Tsatsanis et al., 2006</xref>; <xref ref-type="bibr" rid="B41">Witzel et al., 2010</xref>). Aberrant overactivation or overexpression of these transcription factors has been frequently observed in inflammation-associated disorders (<xref ref-type="bibr" rid="B12">Danese and Mantovani, 2010</xref>). Both cooperate each other, augmenting the inflammatory signal transduction (<xref ref-type="bibr" rid="B9">Bollrath and Greten, 2009</xref>; <xref ref-type="bibr" rid="B26">Lee et al., 2009</xref>; <xref ref-type="bibr" rid="B16">Grivennikov and Karin, 2010</xref>). Under physiological conditions, p65/p50 NF-&#x03BA;B heterodimer remains inactive by forming a complex with inhibitor of &#x03BA;B (I&#x03BA;B&#x03B1;), but becomes activated in response to proinflammatory stimuli through increased phosphorylation and subsequent degradation of I&#x03BA;B&#x03B1; (<xref ref-type="bibr" rid="B17">Hayden and Ghosh, 2004</xref>, <xref ref-type="bibr" rid="B18">2008</xref>; <xref ref-type="bibr" rid="B15">Ghosh and Hayden, 2008</xref>). This liberates functionally active NF-&#x03BA;B which translocates to nucleus where it regulates the expression of target genes, including those that encode COX-2 and iNOS. STAT3, another transcription factor that plays an important role in inflammation, regulates transcription of genes involved in cell proliferation and survival. Activation of STAT3 is dependent on its phosphorylation at the specific tyrosine residue (Y<sup>705</sup>), which facilitates the dimerization of STAT3. The activated STAT3 dimer then translocates into nucleus to promote the transcription of target genes (<xref ref-type="bibr" rid="B2">Aggarwal et al., 2009</xref>; <xref ref-type="bibr" rid="B43">Yue and Turkson, 2009</xref>).</p>
<p>Some synthetic anti-inflammatory agents have been considered to have therapeutic potential in the management of IBD, but in many cases their long-term use causes side effects. In this context, it is worthwhile searching for natural sources of anti-inflammatory substances, especially those that have been used for long period of time in herbal medicine or for a culinary purpose, so their safety has been somehow verified. <italic>Perilla frutescens</italic> (L.) Britt. (Lamiaceae) belongs to an annual herb of the mint family. It contains polyphenols which have structural varieties with a large diversity of biological activities (<xref ref-type="bibr" rid="B5">Asif, 2012</xref>). Their anti-inflammatory effects have been well-documented (<xref ref-type="bibr" rid="B30">Makino et al., 2001</xref>; <xref ref-type="bibr" rid="B35">Ueda and Yamazaki, 2001</xref>; <xref ref-type="bibr" rid="B29">Lim et al., 2014</xref>; <xref ref-type="bibr" rid="B24">Kwak and Ju, 2015</xref>).</p>
<p>Recently, a better understanding of the mechanisms involved in mucosal homeostasis and the occurrence of IBD has been achieved with the advent of animal models of mucosal inflammation. The dextran sulfate sodium (DSS)-induced colitis in mice mimics the pathogenesis of human IBD, and this murine model is hence utilized in preclinical studies for identifying the substances with potential preventive/therapeutic effects on IBD (<xref ref-type="bibr" rid="B40">Wirtz et al., 2007</xref>). In the present study, we investigated the possible protective effects of <italic>Perilla frutescens</italic> extract (PE) against DSS-induced colitis and underlying molecular mechanisms, with special focus on the inflammatory signal transduction mediated by NF-&#x03BA;B and STAT3.</p>
</sec>
<sec id="s1" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec><title>Animals</title>
<p>Four-week-old male ICR mice were purchased from Orient-Bio, Inc. (Seongnam, Republic of Korea). They were acclimated for 1 week with tap water and basal diet under the conventional housing conditions of humidity (50 &#x00B1; 10%), temperature (24 &#x00B1; 2&#x00B0;C), and light (12/12 h of light/dark cycle). All studies were approved by the Institutional Animal Care and Use Committee of Seoul National University.</p>
</sec>
<sec><title>Induction of DSS-Induced Colitis</title>
<p>DSS (MW of 36,000&#x2013;50,000) was obtained from MP Biomedicals, LLC (Solon, OH, United States). PE was obtained from Amino Up Chemical Co., Ltd. (Sapporo, Japan). Groups of six mice were treated for 2 weeks in accordance with the experimental design illustrated in <bold>Figure <xref ref-type="fig" rid="F1">1A</xref></bold>. Acute colitis was induced by DSS (3%, w/v) given in double distilled drinking water for seven consecutive days. Mice in the PE group received PE (20 or 100 mg/kg) 1 week before and during the DSS administration which was dissolved in double distilled water (DDW) once daily by oral gavage. Mice in control and DSS alone groups were also treated with DDW in the same way to get exposed to an equal stress level. In another experiment, PE was given alone at a daily oral dose of 20 or 100 mg/kg for 2 weeks. At the end of the treatment, mice were sacrificed by cervical dislocation. Their colon tissues were taken out and washed with phosphate-buffered saline (PBS). The tissues were separated into several parts for extraction of protein and mRNA. The distal part was fixed in 10% buffered formalin for immunohistochemical examination, and other parts were frozen in liquid nitrogen immediately and kept at -70&#x00B0;C until use.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>Effects of PE on body weight changes and colitis-associated pathologic symptoms in DSS-treated mice. <bold>(A)</bold> Experimental design for evaluating the effects of PE on DSS-induced mouse colitis. <bold>(B)</bold> Five-week-old male ICR mice were treated with 3% DSS in DDW for 7 days. PE (20 or 100 mg/kg) was dissolved in DDW and given orally 7 days before DSS administration and 7 days together with 3% DSS. Changes in the body weight were measured during the period of DSS treatment. <bold>(C)</bold> DAI as the sum of stool consistency and rectal bleeding was scored 0&#x2013;4. Data are expressed as means &#x00B1; SE (<italic>n</italic> = 6 per group). <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01 and <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.001, one-way ANOVA with <italic>post hoc</italic> Tukey&#x2019;s test.</p></caption>
<graphic xlink:href="fphar-08-00482-g001.tif"/>
</fig>
</sec>
<sec><title>Macroscopic Assessment</title>
<p>Since the beginning of the DSS treatment, the body weight of every mice was measured daily. Rectal bleeding and stool consistency were observed and graded from 0 to 4, depending on the severity of blood and diarrhea (<xref ref-type="bibr" rid="B13">Fukata et al., 2005</xref>; <xref ref-type="bibr" rid="B25">Lavi et al., 2010</xref>). Disease Activity Index (DAI) was graded as the sum of scores of rectal bleeding and stool consistency. Colorectal parts were photographed, and their length was measured.</p>
</sec>
<sec><title>Tissue Lysis and Protein Extraction</title>
<p>Mouse colon tissues were homogenized in ice-cold lysis buffer [150 mM NaCl, 0.5% triton-X 100, 50 mM Tris&#x2013;HCl (pH 7.4), 20 mM ethylene glycol tetra acetic acid, 1 mM phenylmethylsulfonyl fluoride (PMSF) and ethylenediaminetetraacetic acid (EDTA)-free cocktail tablet] followed by periodical vortex mixing for 30 min at 0&#x00B0;C. Lysates were centrifuged at 18,000 <italic>g</italic> for 15 min at 4&#x00B0;C. The supernatants were collected and stored at -70&#x00B0;C till use.</p>
</sec>
<sec><title>Western Blot Analysis</title>
<p>For Western blot analysis, the total protein concentration was quantified by using the bicinchoninic acid protein assay kit (Pierce; Rockford, IL, United States). Lysates (30&#x2013;50 &#x03BC;g protein) were mixed and boiled in a sodium dodecyl sulfate (SDS) sample buffer for 5 min. The proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Gelman Laboratory; MI, United States). The blots were blocked in 5% fat-free dry milk in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h at room temperature. The membranes were incubated for 12&#x2013;24 h at 4&#x00B0;C with dilutions of primary antibodies against &#x03B1;-tubulin, actin (Sigma Aldrich, St. Louis, MO, United States), laminB, STAT3, phosphorylated STAT3 (P-STAT3), p65, I&#x03BA;B&#x03B1;, P-I&#x03BA;B&#x03B1;, COX-2, iNOS, CXC chemokine receptor 2 (CXCR2), heme oxygenase-1 (HO-1; Stressgen Biotechnologies Co., San Diego, CA, United States), NF-E2-related factor 2 (Nrf2) and interferon regulatory factor 3 (IRF3; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, United States). The membranes were washed, followed by incubation with 1:4000 dilution of respective horseradish peroxidase (HRP)-conjugated secondary antibody (rabbit, mouse, or goat; Zymed Laboratories; San Francisco, CA, United States) for 2 h, and washed again with TBST. Protein expression was visualized with an enhanced chemiluminescence detection kit (Amersham Pharmacia Biotech; Buckinghamshire, United Kingdom) and LAS-4000 image reader (Fujifilm; Tokyo, Japan) according to the manufacturer&#x2019;s instructions.</p>
</sec>
<sec><title>Fraction of Nuclear and Cytoplasmic Extracts</title>
<p>Cytosolic extracts were obtained from lysates dissolved in hypotonic buffer A [10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; pH 7.8), 1.5 mM MgCl<sub>2</sub>, 10 mM KCl, 1 mM dithiothreitol (DTT), 0.1 mM EDTA, and 0.1 mM PMSF] with 0.1% Nonidet P-40 by homogenization and vortex mixing at 10 min intervals for 3 h. After centrifugation at 18,000 <italic>g</italic> for 15 min, the supernatants (the cytosolic extracts) were collected and stored at -70&#x00B0;C until use. Precipitated pellets were suspended in buffer C [20 mM HEPES (pH 7.8), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, and 20% glycerol]. After centrifugation at 18,000 <italic>g</italic> for 15 min, the supernatants (the nuclear extracts) were collected and stored at -70&#x00B0;C until use.</p>
</sec>
<sec><title>Electrophoretic Mobility Shift Assay</title>
<p>DNA binding activity of NF-&#x03BA;B was measured with electrophoretic mobility shift assay (EMSA). In brief, T4 polynucleotide kinase transferred <sup>32</sup>P labeled &#x03B3;-phosphate from ATP to NF-&#x03BA;B oligonucleotide. After purification with a G-50 micro column (GE Healthcare LS; Buckinghamshire, United Kingdom), the &#x03B3;-<sup>32</sup>P labeled probe was mixed with 10 &#x03BC;g of nuclear extracts and incubation buffer [10 mM Tris&#x2013;HCl (pH 7.5), 100 mM NaCl, 1 mM DTT, 1 mM EDTA, 4% glycerol, and 0.1 mg/ml sonicated salmon sperm DNA]. All the samples were mixed with 2 &#x03BC;l of 0.1% bromophenol blue loading dye after 50 min incubation and separated on 6% non-denatured polyacrylamide gel in a cold room. Finally, gels were dried and exposed to X-ray films (Agfa Healthcare; Mortsel, Belgium).</p>
</sec>
<sec><title>Immunohistochemical Analysis</title>
<p>The dissected colon tissues were prepared for immunohistochemical analysis to measure the expression of COX-2, P-STAT3, and Nrf2. Four-micrometer sections of 10% formalin-fixed and paraffin-embedded tissues were cut on silanized glass slides and deparaffinized three times with xylene and rehydrated through graded alcohol bath. The deparaffinized sections were heated by using microwave and boiled twice for 6 min in 10 mM citrate buffer (pH 6.0) for antigen retrieval. To diminish non-specific staining, each section was treated with 3% hydrogen peroxide and 4% peptone casein blocking solution for 15 min. For the detection of respective protein expression, slides were incubated with COX-2 (Cayman Chemical; Ann Arbor, MI, United States), P-STAT3 (Cell Signaling Technology, Inc.; Beverly, MA, United States) and Nrf2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, United States) antibodies at room temperature for 40 min in Tris-buffered saline containing 0.05% Tween 20, and then developed using respective HRP-conjugated secondary antibodies (rabbit, mouse, or goat) EnVision<sup>TM</sup> System (Dako; Glostrup, Denmark). The peroxidase-binding sites were detected by staining with 3,3&#x2032;-diaminobenzidine tetrahydrochloride (Dako; Glostrup, Denmark). Finally, counterstaining was performed by using Mayer&#x2019;s hematoxylin.</p>
</sec>
<sec><title>Cell Culture</title>
<p>The CCD841CoN cells were obtained from the American Type Culture Collection (Manassas, VA, United States) and maintained in MEM containing 10% fetal bovine serum and an antibiotic&#x2013;antimycotic mixture (Gibco BRL; Grand Island, NY, United States) at 37&#x00B0;C with 5% CO<sub>2</sub> and 95% air. The CCD841CoN cells were treated with PE (10 mg/ml) 1 h before stimulation with 10 ng/ml of tumor necrosis factor-&#x03B1; (TNF-&#x03B1;; R&#x0026;D Inc.; Minneapolis, MN, United States) dissolved in 0.1% bovine serum albumin in PBS. After TNF-&#x03B1; treatment, CCD841CoN cells were incubated for 1 h and prepped. The cells in the apical slide were harvested and centrifuged at 18,000 <italic>g</italic> for 5 min at 4&#x00B0;C. The pellets were suspended in the cell lysis buffer (Cell Signaling Technology; Beverly, MA, United States). After centrifugation at 18,000 <italic>g</italic> for 15 min, the supernatants were collected and stored at -70&#x00B0;C until use.</p>
</sec>
<sec><title>Reverse Transcription PCR</title>
<p>Total RNA was isolated from CCD841CoN cells by using TRIzol<sup>&#x00AE;</sup> (Invitrogen; Carlsbad, CA, United States) according to manufacturer&#x2019;s protocol. One microgram of total RNA reverse transcribed with MLV reverse transcriptase at 42&#x00B0;C for 50 min and at 72&#x00B0;C for 15 min. PCR was conducted according to the standard procedures. The primer sequences used were (forward and reverse, respectively): <italic>cox-2</italic>, 5&#x2032;-GCTGAGCCATACAGCAAATCC-3&#x2032; and 5&#x2032;-GGGAGTCGGGCAATCATCAG-3&#x2032;; <italic>il-6</italic>, 5&#x2032;-GTGTGAAAGCAGCAAAGAGGC-3&#x2032; and 5&#x2032;-CTGGAGGTACTCTAGGTATAC-3&#x2032;; <italic>il-8</italic>, 5&#x2032;-ATGACTTCCAAGCTGGCCGTGGCT-3&#x2032; and 5&#x2032;-TCTCAGCCCTCTTCAAAAACTTCT-3&#x2032;; <italic>gapdh</italic>, 5&#x2032;-AAGGTCGGAGTCAACGGA-3&#x2032; and 5&#x2032;-GCAGTGAGGGTCTCTCTC-3&#x2032;; <italic>interferon (ifn)</italic>-&#x03B1;, 5&#x2032;-AGTGAGCTGACCCAGCAGAT-3&#x2032; and 5&#x2032;-AGACAGCCTTGCAGGTCATT-3&#x2032;; <italic>ifn-&#x03B2;</italic>, 5&#x2032;-CCCTATGGAGATTGACGGAGA-3&#x2032; and 5&#x2032;-ACCCAGTGCTGGAGAAATTG-3&#x2032;; <italic>actin</italic>, 5&#x2032;-AGAGCATAGCCCTCGTAGAT-3&#x2032; and 5&#x2032;-CCCAGAGCAAGAGAGGTATC-3&#x2032;. Amplified products were analyzed on 2% agarose gel electrophoresis, stained with SYBR<sup>&#x00AE;</sup> Green (Invitrogen; Carlsbad, CA, United States) and photographed using fluorescence in LAS-4000.</p>
</sec>
<sec><title>Statistical Analysis</title>
<p>All values presented are the mean &#x00B1; standard error (SE) of at least three independent experiments. Statistical significance was determined by the One-way analysis of variance (ANOVA) with Tukey&#x2019;s <italic>post hoc</italic> test, and <italic>p</italic> &#x003C; 0.05 was considered to be statistically significant. The bar-graphs were analyzed using GraphPad Prism 7 (GraphPad Software, San Diego, CA, United States).</p>
</sec>
</sec>
<sec><title>Results</title>
<sec><title>PE Ameliorated Pathological Symptoms in the DSS-Induced Murine Colitis Model</title>
<p>The body weight of mice in the DSS group became decreased after the day 3 of DSS treatment compared to the control group. However, oral administration of PE attenuated the loss of body weight (<bold>Figure <xref ref-type="fig" rid="F1">1B</xref></bold>). Following the DSS treatment, the DAI score was increased after the day 3. DSS-treated mice exhibited serious symptoms, such as diarrhea and bloody stool. PE treatment reduced the severity of the symptoms (<bold>Figure <xref ref-type="fig" rid="F1">1C</xref></bold>). In addition, shrinkage and thickening of colon occurred as a consequence of colitis caused by DSS (<bold>Figure <xref ref-type="fig" rid="F2">2A</xref></bold>). Oral administration of PE ameliorated the pathological symptoms of colitis. Inhibitory effects of PE against DSS-induced inflammatory events in mouse colon were also verified by histological, immunohistochemical, and immunoblot analyses. Colorectal tissues from DSS-treated mice showed collapse and expansion of epithelium which were accompanied by infiltration of inflammatory cells (<bold>Figure <xref ref-type="fig" rid="F2">2B</xref></bold>) and overexpression of COX-2, iNOS, and cyclin D1 (<bold>Figures <xref ref-type="fig" rid="F3">3A,B</xref></bold>). Thus, PE protected the epithelium from DSS-induced colitis as evidenced by attenuation of morphological and biochemical alterations related to inflammatory colonic tissue damage.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p>Inhibition of DSS-induced shortening of the colon length and inflammatory cell infiltration by PE. <bold>(A)</bold> The comparison of colon length. Data are expressed as means &#x00B1; SE (<italic>n</italic> = 6 per group). <sup>&#x2217;</sup><italic>p</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.001, and <sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.0001, one-way ANOVA with <italic>post hoc</italic> Tukey&#x2019;s test. <bold>(B)</bold> The histochemical analysis of colonic mucosa. Collapse and expansion of epithelium were evident in the colon of DSS-treated mice, and these were attenuated by PE administration. Magnification, &#x00D7;200.</p></caption>
<graphic xlink:href="fphar-08-00482-g002.tif"/>
</fig>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p>Effects of PE on expression of inflammatory and proliferation markers in DSS-induced mouse colitis. <bold>(A)</bold> Immunohistochemical detection of COX-2. The brown dots represent COX-2 expressing cells. Magnification, &#x00D7;200. <bold>(B)</bold> Expression of COX-2, iNOS and cyclin D1 in colonic mucosa detected by Western blot analysis. Experimental conditions and other details are described in Section &#x201C;Materials and Methods.&#x201D; Data are expressed as means &#x00B1; SE (<italic>n</italic> = 6 per group). <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.001, and <sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.0001, one-way ANOVA with <italic>post hoc</italic> Tukey&#x2019;s test.</p></caption>
<graphic xlink:href="fphar-08-00482-g003.tif"/>
</fig>
</sec>
<sec><title>PE Inhibited DSS-Induced Activation of NF-&#x03BA;B and STAT3 Pathways in Mouse Colitis</title>
<p>NF-&#x03BA;B is a transcription factor regulating expression of COX-2 and iNOS. It is activated in IBD (<xref ref-type="bibr" rid="B6">Atreya et al., 2008</xref>), resulting in disorders of the immune system, elevation of cell survival, and reduction of apoptosis (<xref ref-type="bibr" rid="B1">Aggarwal, 2004</xref>). NF-&#x03BA;B activation and translocation into nucleus are dependent on phosphorylation and degradation of I&#x03BA;B&#x03B1;. DSS administration stimulated phosphorylation and subsequent degradation of I&#x03BA;B&#x03B1;, thereby augmenting nuclear translocation of p65, a functionally active subunit of NF-&#x03BA;B. Treatment with PE (100 mg/kg) inhibited the phosphorylation and degradation of I&#x03BA;B&#x03B1; and nuclear migration of p65 (<bold>Figure <xref ref-type="fig" rid="F4">4A</xref></bold>). Likewise, the DSS-induced DNA binding activity of NF-&#x03BA;B in colonic mucosa was reduced by the PE administration (<bold>Figure <xref ref-type="fig" rid="F4">4B</xref></bold>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p>Inhibitory effects of PE on DSS-induced activation of NF-&#x03BA;B signaling. <bold>(A)</bold> Cytosolic extracts and nuclear extracts were subjected to Western blot analysis to detect I&#x03BA;B&#x03B1; (total and phosphorylated) and p65. Data are expressed as means &#x00B1; SE (<italic>n</italic> = 6 per group). <sup>&#x2217;</sup><italic>p</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.001 and <sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.0001, one-way ANOVA with <italic>post hoc</italic> Tukey&#x2019;s test. <bold>(B)</bold> DNA binding activity of NF-&#x03BA;B was measured by EMSA as described in Section &#x201C;Materials and Methods.&#x201D;</p></caption>
<graphic xlink:href="fphar-08-00482-g004.tif"/>
</fig>
<p>STAT3 is mainly activated via the interleukin (IL)-6-gp130-JAK axis, leading to phosphorylation on Tyr705. After dimerization, it translocates into nucleus and regulates transcription of target genes by binding to their promoters. The level of P-STAT3 in the colonic tissue was increased by DSS administration (<bold>Figure <xref ref-type="fig" rid="F5">5A</xref></bold>), but the phosphorylation and nuclear translocation of STAT3 were significantly inhibited by PE (100 mg/kg) (<bold>Figures <xref ref-type="fig" rid="F5">5A,B</xref></bold>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption><p>Inhibition of DSS-induced phosphorylation of STAT3 by PE. <bold>(A)</bold> Immunohistochemical detection of STAT3 in the colonic mucosa. Magnification, &#x00D7;200. <bold>(B)</bold> Protein lysates from total and nuclear extracts of colonic mucosa were used to measure the expression of P-STAT3 as well as STAT3. Data are expressed as means &#x00B1; SE (<italic>n</italic> = 6 per group). <sup>&#x2217;</sup><italic>p</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.001, and <sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.0001, one-way ANOVA with <italic>post hoc</italic> Tukey&#x2019;s test.</p></caption>
<graphic xlink:href="fphar-08-00482-g005.tif"/>
</fig>
</sec>
<sec><title>PE Attenuated TNF-&#x03B1;-Induced Expression of Inflammatory Factors in Cultured Human Colon Epithelial Cells</title>
<p>TNF-&#x03B1; is a pleiotropic inflammatory cytokine and a central regulator of inflammation. TNF-&#x03B1; activates NF-&#x03BA;B and MAPK signaling (<xref ref-type="bibr" rid="B7">Bendtzen et al., 2009</xref>). CCD841CoN human colon epithelial cells were stimulated with TNF-&#x03B1; (10 ng/ml). Phosphorylation of I&#x03BA;B&#x03B1; and STAT3 was increased in 15 min and 1 h, respectively after TNF-&#x03B1; treatment (<bold>Figure <xref ref-type="fig" rid="F6">6A</xref></bold>). IL-6 plays a role not only in acute inflammation, but also in chronic inflammation by changing the nature of leukocytes and modulating some immune cells, such as T- and B-cells. IL-8 is involved in promotion of neutrophil infiltration. TNF-&#x03B1; treatment induced the expression of genes encoding both proteins at 1 h (<bold>Figure <xref ref-type="fig" rid="F6">6B</xref></bold>). CXCR2 is a receptor for inflammatory chemokines, such as IL-8. Treatment with PE (10 mg/ml) 1 h prior to TNF-&#x03B1; reduced the expression levels of CXCR2 and some representative mediators involved in inflammatory signaling, such as iNOS, P-I&#x03BA;B&#x03B1;, and P-STAT3 (<bold>Figure <xref ref-type="fig" rid="F6">6C</xref></bold>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption><p>Effects of PE on inflammatory signaling in the CCD841CoN human normal colon cell line stimulated with TNF-&#x03B1;. TNF-&#x03B1; (10 ng/ml) was treated to CCD841CoN for the indicated time periods. The protein <bold>(A)</bold> and mRNA <bold>(B)</bold> levels of inflammatory factors were measured by Western blot assay and RT-PCR, respectively. <bold>(C)</bold> The effects of PE on expression of proinflammatory factors. The cells were treated with TNF-&#x03B1; (10 ng/ml) and PE (10 mg/ml), and whole lysates were subjected to Western blot analysis.</p></caption>
<graphic xlink:href="fphar-08-00482-g006.tif"/>
</fig>
</sec>
<sec><title>PE Inhibited DSS-Induced Activation of IRF3 Signaling in Mouse Colitis</title>
<p>Toll-like receptor 4 (TLR4) is an upstream signaling molecule involved in NF-kB activation and pathogenesis of IBD. TLR4 expression has been shown to be upregulated in the colonic mucosa of DSS-induced colitis (<xref ref-type="bibr" rid="B44">Zhang et al., 2014</xref>). One of the key mediators of TLR4 signaling is IRF3 that encodes type I interferon (IFN), such as IFN-&#x03B1; and IFN-&#x03B2;. We noticed that there was robust accumulation of IRF3 and expression of <italic>ifn-&#x03B1;</italic> and <italic>ifn-&#x03B2;</italic> in the colonic mucosa of DSS-treated mice (<bold>Figure <xref ref-type="fig" rid="F7">7</xref></bold>). PE administration suppressed the expression of IRF3 (<bold>Figure <xref ref-type="fig" rid="F7">7A</xref></bold>) and its target genes (<bold>Figure <xref ref-type="fig" rid="F7">7B</xref></bold>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption><p>Inhibitory effects of PE on DSS-induced activation of IRF3 signaling in mouse colitis. <bold>(A)</bold> Expression of IRF3 in colonic mucosa was detected by Western blot analysis. <bold>(B)</bold> The mRNA levels of <italic>ifn-&#x03B1;</italic> and <italic>ifn-&#x03B2;</italic> were measured by RT-PCR. Experimental conditions and other details are described in Section &#x201C;Materials and Methods.&#x201D; Data are expressed as means &#x00B1; SE. <sup>&#x2217;</sup><italic>p</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.001, and <sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.0001, one-way ANOVA with <italic>post hoc</italic> Tukey&#x2019;s test.</p></caption>
<graphic xlink:href="fphar-08-00482-g007.tif"/>
</fig>
</sec>
<sec><title>PE Upregulated the Expression of Nrf2 and its Target Protein HO-1 in the Colon of Mice</title>
<p>DSS administration caused not only inflammation, but also oxidative mucosal damage as revealed by increased accumulation of 4-HNE-modified protein (<bold>Figure <xref ref-type="fig" rid="F8">8A</xref></bold>). PE administration attenuated the DSS-induced oxidative stress. Nrf2 is a transcription factor encoded by the <italic>NFE2L2</italic> gene and regulates the expression of many antioxidant enzymes and other stress-responsive proteins, including HO-1 (<xref ref-type="bibr" rid="B31">Moi et al., 1994</xref>). PE enhanced the expression of HO-1 as well as Nrf2 (<bold>Figure <xref ref-type="fig" rid="F8">8B</xref></bold>). The colonic accumulation of Nrf2 was further verified by immunohistochemical analysis (<bold>Figure <xref ref-type="fig" rid="F8">8C</xref></bold>). The nuclear localization of Nrf2 was also enhanced by PE (<bold>Figure <xref ref-type="fig" rid="F8">8D</xref></bold>).</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption><p>Attenuation of DSS-induced oxidative damage and upregulation of the antioxidant signaling in mouse colon. <bold>(A)</bold> Western blot analysis of 4-HNE-modified protein. <bold>(B)</bold> Effects of PE on expression of Nrf2 and HO-1. To compare the expression of Nrf2 and HO-1, the whole lysates of the colon from vehicle- or PE-treated (20 or 100 mg/kg once a day for 2 weeks) mice were prepared and subjected to Western blot analysis. Data are expressed as means &#x00B1; SE. <sup>&#x2217;</sup><italic>p</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.001, and <sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.0001, one-way ANOVA with <italic>post hoc</italic> Tukey&#x2019;s test. <bold>(C)</bold> Immunohistochemical detection of Nrf2 in the colon of mice treated with PE (100 mg/kg) for 2 weeks. <bold>(D)</bold> Effects of PE (100 mg/kg) on nuclear localization of Nrf2 in mouse colon.</p></caption>
<graphic xlink:href="fphar-08-00482-g008.tif"/>
</fig>
</sec>
</sec>
<sec><title>Discussion</title>
<p>Both NF-&#x03BA;B and STAT3 contribute to inflammation and carcinogenesis by cooperating each other (<xref ref-type="bibr" rid="B26">Lee et al., 2009</xref>; <xref ref-type="bibr" rid="B16">Grivennikov and Karin, 2010</xref>). COX-2 is one of the major target proteins of NF-&#x03BA;B. Dysregulation of cell cycle control plays a key role in carcinogenesis. Cyclin D1 is a key protein that regulates the cell cycle transition from G<sub>1</sub> to S phase. Cyclin D1 is transcriptionally regulated by STAT3 and required for neoplastic transformation (<xref ref-type="bibr" rid="B28">Leslie et al., 2006</xref>). It is interesting to note that COX-2, as a major target of NF-&#x03BA;B, has been found to stimulate human urothelial cell proliferation induced by inorganic arsenic through upregulation of cyclin D1 (<xref ref-type="bibr" rid="B38">Wang et al., 2015</xref>). We noticed that cyclin D1 was overexpressed together with COX-2 and another inflammatory enzyme iNOS in DSS-induced colitis, and this was suppressed by PE administration. DSS-induced colitis is also accompanied by oxidative tissue damages. Thus, the colonic mucosa from DSS-treated mice showed elevated accumulation of 4-HNE-modified protein, a biochemical hallmark of oxidative stress. PE upregulated the expression of a prototypic antioxidant enzyme, HO-1 and its master regulator Nrf2. As oxidative stress and inflammation are closely linked, it would be suggested that PE inhibits DSS-induced colitis by fortifying the tissue antioxidant defense system.</p>
<p>While our study was in progress, <xref ref-type="bibr" rid="B36">Urushima et al. (2015)</xref> reported that 0.54% PE administered for 7 days simultaneously with 1.5% DSS or for 10 days following 1.5% DSS treatment for 5 days ameliorated pathogenic symptoms of colitis in 8-week-old C57BL/6 female mice while it improved the body weight loss. They found that serum levels of TNF-&#x03B1;, IL-17A, and IL-10 were significantly reduced by co-administration of PE. When PE was given after the DSS treatment, there was a marked elevation of the serum TGF-&#x03B2; level whereas the mRNA expression of TNF-&#x03B1; and IL-17A was significantly down-regulated in the distal colon. Our <italic>in vitro</italic> study revealed that stimulation of human colon epithelial cells with TNF-&#x03B1; resulted in upregulation of some proinflammatory gene expression. IL-6 is a pleiotropic cytokine that is produced at the site of inflammation and plays a key role in the acute inflammatory response (<xref ref-type="bibr" rid="B42">Xing et al., 1998</xref>). However, IL-6 is also considered to dictate the transition from acute to chronic inflammation by changing the nature of leukocytes. In addition, IL-6 exerts stimulatory effects on T- and B-cells, thus favoring chronic inflammatory responses (<xref ref-type="bibr" rid="B14">Gabay, 2006</xref>). IL-8 is a chemokine produced by macrophages and other cell types, such as epithelial cells, and attracts and activates neutrophils in inflamed sites (<xref ref-type="bibr" rid="B8">Bickel, 1993</xref>). CXCR2 is a receptor for IL-8, and their interaction triggers neutrophil infiltration into epithelial tissues, making them inflamed (<xref ref-type="bibr" rid="B20">Katoh et al., 2013</xref>). We found that PE treatment to human colon epithelial cells inhibited the expression of TNF-a-induced CXCR2 expression. Taken all these into account, the protective effect of PE against DSS-induced colitis is attributable, at least in part, to its modulation of immune cell functions. Our preliminary studies have revealed that PE treatment to murine macrophages inhibits the LPS-induced expression of proinflammatory cytokines and enhances their phagocytic activity in terms of engulfing apoptotic neutrophils (DD Park et al., unpublished observation).</p>
<p>The transcription factor, IRF3 plays an indispensable role in innate host immune response to microbial infection. IRF3 has been shown to have an anti-inflammatory function (<xref ref-type="bibr" rid="B11">Carrigan et al., 2010</xref>), but a recent study also reveals that it can mediate the pro-inflammatory signals (<xref ref-type="bibr" rid="B23">Kumari et al., 2016</xref>). In our present study, DSS treatment resulted in pronounced induction of IRF3 and two of its principal target genes, <italic>ifn-&#x03B1;</italic> and <italic>ifn-&#x03B2;</italic>, and this was repressed by PE administration. It has been reported that rebamipide, used in Japan for the treatment of gastric ulcers and other gastrointestinal disorders, inhibited the DSS-induced IRF3 upregulation (<xref ref-type="bibr" rid="B32">Ogasawara et al., 2011</xref>). Myeloid derived suppressor cells (MDSCs) are immature myeloid cells that comprise a heterogeneous immune cell population. The proportion of MDSCs increases in inflammation and infection. Development of solid cancer depends on escape from host immune surveillance. MDSCs play pivotal roles in suppression of host immune responses through multiple mechanisms (<xref ref-type="bibr" rid="B39">Wesolowski et al., 2013</xref>; <xref ref-type="bibr" rid="B21">Katoh and Watanabe, 2015</xref>). STAT3 activation promotes expansion of MDSCs, providing a permissive immune environment necessary for the growth of malignant cells. Therefore, STAT3 and related pathways may serve as a target for changing the tumor immunologic microenvironment to benefit cancer immunotherapies (<xref ref-type="bibr" rid="B27">Lee et al., 2011</xref>). It would be worthwhile investigating the effects of PE and it active constituents on the recovery of immune surveillance in inflammation-associated intestinal carcinogenesis.</p>
<p>PE extract (150 mg, twice a day, <italic>p.o.</italic>) has been reported to improve gastrointestinal discomfort in a double-blind, randomized, placebo-controlled study (<xref ref-type="bibr" rid="B10">Buchwald-Werner et al., 2014</xref>). PE contains many polyphenols and some of them have strong anti-inflammatory and antioxidant effects (<xref ref-type="bibr" rid="B45">Zhou et al., 2014</xref>). Major components of PE are caffeic acid, rosmarinic acid, luteolin, and apigenin. Luteolin suppressed production of proinflammatory cytokines, such as TNF-&#x03B1;, IL-1&#x03B2;, IL-6, and IL-17A in cultured monocytes derived from the 8-week-old wild-type C57/BL6 female mice. Apigenin also suppressed secretion of IL-17A while it increased the anti-inflammatory cytokine IL-10, whereas rosmarinic acid increased the regulatory T cell population (<xref ref-type="bibr" rid="B36">Urushima et al., 2015</xref>). Rosmarinic acid has recently been shown to suppresses DSS-induced colitis which is attributed to its dual inhibition of NF-&#x03BA;B and STAT3 activation (<xref ref-type="bibr" rid="B19">Jin et al., 2017</xref>).</p>
<p>In summary, PE administration ameliorated the experimentally induced colitis in mice. The protective effects of PE appear to be associated with blockade of proinflammatory signaling mediated by NF-&#x03BA;B and STAT3 and potentiation of Nrf2-mediated antioxidant defense as schematically illustrated in <bold>Figure <xref ref-type="fig" rid="F9">9</xref></bold>. These findings suggest that PE can be considered for use in the management of IBD, and further clinical studies will be necessary to evaluate its safety and therapeutic efficacy and to identify an active principle.</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption><p>Proposed scheme illustrating the biochemical mechanisms underlying protective effects of PE against DSS-induced mouse colitis. PE inhibits pro-inflammatory signaling mediated by NF-kB and STAT3 while it activates the Nrf2-induced antioxidant signaling.</p></caption>
<graphic xlink:href="fphar-08-00482-g009.tif"/>
</fig>
</sec>
<sec><title>Author Contributions</title>
<p>DDP conducted a majority of experiments and wrote the manuscript; H-WY, XZ, SeuHK, D-HK, and S-JK helped experiments and provided experimental materials and techniques; SeoHK conducted experiments required for revision; H-KN advised the experiments and participated in discussion; AS and TM supplied the <italic>Perilla frutescens</italic> and provided relevant information for revision; Y-JS guided the entire study and edited the manuscript.</p>
</sec>
<sec><title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This work was supported by a Global Core Research Center grant from the National Research Foundation, Republic of Korea (grant number 2011-0030001) and by the collaborative research project with the Amino Up Chemical Co., Ltd., Japan.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname> <given-names>B. B.</given-names></name></person-group> (<year>2004</year>). <article-title>Nuclear factor-&#x03BA;B: the enemy within.</article-title> <source><italic>Cancer Cell</italic></source> <volume>6</volume> <fpage>203</fpage>&#x2013;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2004.09.003</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname> <given-names>B. B.</given-names></name> <name><surname>Kunnumakkara</surname> <given-names>A. B.</given-names></name> <name><surname>Harikumar</surname> <given-names>K. B.</given-names></name> <name><surname>Gupta</surname> <given-names>S. R.</given-names></name> <name><surname>Tharakan</surname> <given-names>S. T.</given-names></name> <name><surname>Koca</surname> <given-names>C.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Signal transducer and activator of transcription-3 inflammation, and cancer: how intimate is the relationship?</article-title> <source><italic>Ann. N. Y. Acad. Sci.</italic></source> <volume>1171</volume> <fpage>59</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.04911.x</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aktan</surname> <given-names>F.</given-names></name></person-group> (<year>2004</year>). <article-title>iNOS-mediated nitric oxide production and its regulation.</article-title> <source><italic>Life Sci.</italic></source> <volume>75</volume> <fpage>639</fpage>&#x2013;<lpage>653</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2003.10.042</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ananthakrishnan</surname> <given-names>A. N.</given-names></name></person-group> (<year>2015</year>). <article-title>Epidemiology and risk factors for IBD.</article-title> <source><italic>Nat. Rev. Gastroenterol. Hepatol.</italic></source> <volume>12</volume> <fpage>205</fpage>&#x2013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1038/nrgastro.2015.34</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asif</surname> <given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Phytochemical study of polyphenols in <italic>Perilla frutescens</italic> as an antioxidant.</article-title> <source><italic>Avicenna J. Phytomed.</italic></source> <volume>2</volume> <fpage>169</fpage>&#x2013;<lpage>178</lpage>.</citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atreya</surname> <given-names>I.</given-names></name> <name><surname>Atreya</surname> <given-names>R.</given-names></name> <name><surname>Neurath</surname> <given-names>M. F.</given-names></name></person-group> (<year>2008</year>). <article-title>NF-&#x03BA;B in inflammatory bowel disease.</article-title> <source><italic>J. Intern. Med.</italic></source> <volume>263</volume> <fpage>591</fpage>&#x2013;<lpage>596</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2796.2008.01953.x</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bendtzen</surname> <given-names>K.</given-names></name> <name><surname>Ainsworth</surname> <given-names>M.</given-names></name> <name><surname>Steenholdt</surname> <given-names>C.</given-names></name> <name><surname>Thomsen</surname> <given-names>O. O.</given-names></name> <name><surname>Brynskov</surname> <given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-&#x03B1; antibodies.</article-title> <source><italic>Scand. J. Gastroenterol.</italic></source> <volume>44</volume> <fpage>774</fpage>&#x2013;<lpage>781</lpage>. <pub-id pub-id-type="doi">10.1080/00365520802699278</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bickel</surname> <given-names>M.</given-names></name></person-group> (<year>1993</year>). <article-title>The role of interleukin-8 in inflammation and mechanisms of regulation.</article-title> <source><italic>J. Periodontol.</italic></source> <volume>64(Suppl. 5)</volume> <fpage>456</fpage>&#x2013;<lpage>460</lpage>.</citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bollrath</surname> <given-names>J.</given-names></name> <name><surname>Greten</surname> <given-names>F. R.</given-names></name></person-group> (<year>2009</year>). <article-title>IKK/NF-&#x03BA;B and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis.</article-title> <source><italic>EMBO Rep.</italic></source> <volume>10</volume> <fpage>1314</fpage>&#x2013;<lpage>1319</lpage>. <pub-id pub-id-type="doi">10.1038/embor.2009.243</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchwald-Werner</surname> <given-names>S.</given-names></name> <name><surname>Fujii</surname> <given-names>H.</given-names></name> <name><surname>Reule</surname> <given-names>C.</given-names></name> <name><surname>Schoen</surname> <given-names>C.</given-names></name></person-group> (<year>2014</year>). <article-title>Perilla extract improves gastrointestinal discomfort in a randomized placebo controlled double blind human pilot study.</article-title> <source><italic>BMC Complement. Altern. Med.</italic></source> <volume>14</volume>:<issue>173</issue>. <pub-id pub-id-type="doi">10.1186/1472-6882-14-173</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carrigan</surname> <given-names>S. O.</given-names></name> <name><surname>Junkins</surname> <given-names>R.</given-names></name> <name><surname>Yang</surname> <given-names>Y. J.</given-names></name> <name><surname>Macneil</surname> <given-names>A.</given-names></name> <name><surname>Richardson</surname> <given-names>C.</given-names></name> <name><surname>Johnston</surname> <given-names>B.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>IFN regulatory factor 3 contributes to the host response during <italic>Pseudomonas aeruginosa</italic> lung infection in mice.</article-title> <source><italic>J. Immunol.</italic></source> <volume>185</volume> <fpage>3602</fpage>&#x2013;<lpage>3609</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0903429</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danese</surname> <given-names>S.</given-names></name> <name><surname>Mantovani</surname> <given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer.</article-title> <source><italic>Oncogene</italic></source> <volume>29</volume> <fpage>3313</fpage>&#x2013;<lpage>3323</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2010.109</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukata</surname> <given-names>M.</given-names></name> <name><surname>Michelsen</surname> <given-names>K. S.</given-names></name> <name><surname>Eri</surname> <given-names>R.</given-names></name> <name><surname>Thomas</surname> <given-names>L. S.</given-names></name> <name><surname>Hu</surname> <given-names>B.</given-names></name> <name><surname>Lukasek</surname> <given-names>K.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis.</article-title> <source><italic>Am. J. Physiol. Gastrointest. Liver Physiol.</italic></source> <volume>288</volume> <fpage>G1055</fpage>&#x2013;<lpage>G1065</lpage>. <pub-id pub-id-type="doi">10.1152/ajpgi.00328.2004</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabay</surname> <given-names>C.</given-names></name></person-group> (<year>2006</year>). <article-title>Interleukin-6 and chronic inflammation.</article-title> <source><italic>Arthritis Res. Ther.</italic></source> <volume>8(Suppl. 2)</volume> <issue>S3</issue>. <pub-id pub-id-type="doi">10.1186/ar1917</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname> <given-names>S.</given-names></name> <name><surname>Hayden</surname> <given-names>M. S.</given-names></name></person-group> (<year>2008</year>). <article-title>New regulators of NF-&#x03BA;B in inflammation.</article-title> <source><italic>Nat. Rev. Immunol.</italic></source> <volume>8</volume> <fpage>837</fpage>&#x2013;<lpage>848</lpage>. <pub-id pub-id-type="doi">10.1038/nri2423</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grivennikov</surname> <given-names>S. I.</given-names></name> <name><surname>Karin</surname> <given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>Dangerous liaisons: STAT3 and NF-&#x03BA;B collaboration and crosstalk in cancer.</article-title> <source><italic>Cytokine Growth Factor Rev.</italic></source> <volume>21</volume> <fpage>11</fpage>&#x2013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.cytogfr.2009.11.005</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname> <given-names>M. S.</given-names></name> <name><surname>Ghosh</surname> <given-names>S.</given-names></name></person-group> (<year>2004</year>). <article-title>Signaling to NF-&#x03BA;B.</article-title> <source><italic>Genes Dev.</italic></source> <volume>18</volume> <fpage>2195</fpage>&#x2013;<lpage>2224</lpage>. <pub-id pub-id-type="doi">10.1101/gad.1228704</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname> <given-names>M. S.</given-names></name> <name><surname>Ghosh</surname> <given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Shared principles in NF-&#x03BA;B signaling.</article-title> <source><italic>Cell</italic></source> <volume>132</volume> <fpage>344</fpage>&#x2013;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.01.020</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>B. R.</given-names></name> <name><surname>Chung</surname> <given-names>K. S.</given-names></name> <name><surname>Cheon</surname> <given-names>S. Y.</given-names></name> <name><surname>Lee</surname> <given-names>M.</given-names></name> <name><surname>Hwang</surname> <given-names>S.</given-names></name> <name><surname>Noh Hwang</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-&#x03BA;B and STAT3 activation.</article-title> <source><italic>Sci. Rep.</italic></source> <volume>7</volume>:<issue>46252</issue>. <pub-id pub-id-type="doi">10.1038/srep46252</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katoh</surname> <given-names>H.</given-names></name> <name><surname>Wang</surname> <given-names>D.</given-names></name> <name><surname>Daikoku</surname> <given-names>T.</given-names></name> <name><surname>Sun</surname> <given-names>H.</given-names></name> <name><surname>Dey</surname> <given-names>S. K.</given-names></name> <name><surname>Dubois</surname> <given-names>R. N.</given-names></name></person-group> (<year>2013</year>). <article-title>CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis.</article-title> <source><italic>Cancer Cell</italic></source> <volume>24</volume> <fpage>631</fpage>&#x2013;<lpage>644</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2013.10.009</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katoh</surname> <given-names>H.</given-names></name> <name><surname>Watanabe</surname> <given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Myeloid-derived suppressor cells and therapeutic strategies in cancer.</article-title> <source><italic>Mediat. Inflamm.</italic></source> <volume>2015</volume>:<issue>159269</issue>. <pub-id pub-id-type="doi">10.1155/2015/159269</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>E. R.</given-names></name> <name><surname>Chang</surname> <given-names>D. K.</given-names></name></person-group> (<year>2014</year>). <article-title>Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis.</article-title> <source><italic>World J. Gastroenterol.</italic></source> <volume>20</volume> <fpage>9872</fpage>&#x2013;<lpage>9881</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v20.i29.9872</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname> <given-names>M.</given-names></name> <name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Lantier</surname> <given-names>L.</given-names></name> <name><surname>Lyubetskaya</surname> <given-names>A.</given-names></name> <name><surname>Eguchi</surname> <given-names>J.</given-names></name> <name><surname>Kang</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>IRF3 promotes adipose inflammation and insulin resistance and represses browning.</article-title> <source><italic>J. Clin. Invest.</italic></source> <volume>126</volume> <fpage>2839</fpage>&#x2013;<lpage>2854</lpage>. <pub-id pub-id-type="doi">10.1172/JCI86080</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname> <given-names>Y.</given-names></name> <name><surname>Ju</surname> <given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Inhibitory activities of <italic>Perilla frutescens</italic> britton leaf extract against the growth, migration, and adhesion of human cancer cells.</article-title> <source><italic>Nutr. Res. Pract.</italic></source> <volume>9</volume> <fpage>11</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.4162/nrp.2015.9.1.11</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavi</surname> <given-names>I.</given-names></name> <name><surname>Levinson</surname> <given-names>D.</given-names></name> <name><surname>Peri</surname> <given-names>I.</given-names></name> <name><surname>Nimri</surname> <given-names>L.</given-names></name> <name><surname>Hadar</surname> <given-names>Y.</given-names></name> <name><surname>Schwartz</surname> <given-names>B.</given-names></name></person-group> (<year>2010</year>). <article-title>Orally administered glucans from the edible mushroom <italic>Pleurotus pulmonarius</italic> reduce acute inflammation in dextran sulfate sodium-induced experimental colitis.</article-title> <source><italic>Br. J. Nutr.</italic></source> <volume>103</volume> <fpage>393</fpage>&#x2013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1017/S0007114509991760</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>H.</given-names></name> <name><surname>Herrmann</surname> <given-names>A.</given-names></name> <name><surname>Deng</surname> <given-names>J. H.</given-names></name> <name><surname>Kujawski</surname> <given-names>M.</given-names></name> <name><surname>Niu</surname> <given-names>G.</given-names></name> <name><surname>Li</surname> <given-names>Z.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Persistently activated Stat3 maintains constitutive NF-&#x03BA;B activity in tumors.</article-title> <source><italic>Cancer Cell</italic></source> <volume>15</volume> <fpage>283</fpage>&#x2013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2009.02.015</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>H.</given-names></name> <name><surname>Pal</surname> <given-names>S. K.</given-names></name> <name><surname>Reckamp</surname> <given-names>K.</given-names></name> <name><surname>Figlin</surname> <given-names>R. A.</given-names></name> <name><surname>Yu</surname> <given-names>H.</given-names></name></person-group> (<year>2011</year>). <article-title>STAT3: a target to enhance antitumor immune response.</article-title> <source><italic>Curr. Top. Microbiol. Immunol.</italic></source> <volume>344</volume> <fpage>41</fpage>&#x2013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1007/82-2010-51</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leslie</surname> <given-names>K.</given-names></name> <name><surname>Lang</surname> <given-names>C.</given-names></name> <name><surname>Devgan</surname> <given-names>G.</given-names></name> <name><surname>Azare</surname> <given-names>J.</given-names></name> <name><surname>Berishaj</surname> <given-names>M.</given-names></name> <name><surname>Gerald</surname> <given-names>W.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.</article-title> <source><italic>Cancer Res.</italic></source> <volume>66</volume> <fpage>2544</fpage>&#x2013;<lpage>2552</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2203</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname> <given-names>H. J.</given-names></name> <name><surname>Woo</surname> <given-names>K. W.</given-names></name> <name><surname>Lee</surname> <given-names>K. R.</given-names></name> <name><surname>Lee</surname> <given-names>S. K.</given-names></name> <name><surname>Kim</surname> <given-names>H. P.</given-names></name></person-group> (<year>2014</year>). <article-title>Inhibition of proinflammatory cytokine generation in lung inflammation by the leaves of <italic>Perilla frutescens</italic> and its constituents.</article-title> <source><italic>Biomol. Ther.</italic></source> <volume>22</volume> <fpage>62</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.4062/biomolther.2013.088</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Makino</surname> <given-names>T.</given-names></name> <name><surname>Furuta</surname> <given-names>A.</given-names></name> <name><surname>Fujii</surname> <given-names>H.</given-names></name> <name><surname>Nakagawa</surname> <given-names>T.</given-names></name> <name><surname>Wakushima</surname> <given-names>H.</given-names></name> <name><surname>Saito</surname> <given-names>K.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Effect of oral treatment of <italic>Perilla frutescens</italic> and its constituents on type-I allergy in mice.</article-title> <source><italic>Biol. Pharm. Bull.</italic></source> <volume>24</volume> <fpage>1206</fpage>&#x2013;<lpage>1209</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.24.1206</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moi</surname> <given-names>P.</given-names></name> <name><surname>Chan</surname> <given-names>K.</given-names></name> <name><surname>Asunis</surname> <given-names>I.</given-names></name> <name><surname>Cao</surname> <given-names>A.</given-names></name> <name><surname>Kan</surname> <given-names>Y. W.</given-names></name></person-group> (<year>1994</year>). <article-title>Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the <italic>&#x03B2;</italic>-globin locus control region.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>91</volume> <fpage>9926</fpage>&#x2013;<lpage>9930</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.91.21.9926</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ogasawara</surname> <given-names>N.</given-names></name> <name><surname>Sasaki</surname> <given-names>M.</given-names></name> <name><surname>Itoh</surname> <given-names>Y.</given-names></name> <name><surname>Tokudome</surname> <given-names>K.</given-names></name> <name><surname>Kondo</surname> <given-names>Y.</given-names></name> <name><surname>Ito</surname> <given-names>Y.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Rebamipide suppresses TLR-TBK1 signaling pathway resulting in regulating IRF3/7 and IFN-&#x03B1;/&#x03B2; reduction.</article-title> <source><italic>J. Clin. Biochem. Nutr.</italic></source> <volume>48</volume> <fpage>154</fpage>&#x2013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.3164/jcbn.10-69</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname> <given-names>L. A.</given-names></name> <name><surname>Bray</surname> <given-names>F.</given-names></name> <name><surname>Siegel</surname> <given-names>R. L.</given-names></name> <name><surname>Ferlay</surname> <given-names>J.</given-names></name> <name><surname>Lortet-Tieulent</surname> <given-names>J.</given-names></name> <name><surname>Jemal</surname> <given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Global cancer statistics, 2012.</article-title> <source><italic>CA Cancer J. Clin.</italic></source> <volume>65</volume> <fpage>87</fpage>&#x2013;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21262</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsatsanis</surname> <given-names>C.</given-names></name> <name><surname>Androulidaki</surname> <given-names>A.</given-names></name> <name><surname>Venihaki</surname> <given-names>M.</given-names></name> <name><surname>Margioris</surname> <given-names>A. N.</given-names></name></person-group> (<year>2006</year>). <article-title>Signalling networks regulating cyclooxygenase-2.</article-title> <source><italic>Int. J. Biochem. Cell Biol.</italic></source> <volume>38</volume> <fpage>1654</fpage>&#x2013;<lpage>1661</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2006.03.021</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname> <given-names>H.</given-names></name> <name><surname>Yamazaki</surname> <given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Anti-inflammatory and anti-allergic actions by oral administration of a perilla leaf extract in mice.</article-title> <source><italic>Biosci. Biotechnol. Biochem.</italic></source> <volume>65</volume> <fpage>1673</fpage>&#x2013;<lpage>1675</lpage>. <pub-id pub-id-type="doi">10.1271/bbb.65.1673</pub-id></citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Urushima</surname> <given-names>H.</given-names></name> <name><surname>Nishimura</surname> <given-names>J.</given-names></name> <name><surname>Mizushima</surname> <given-names>T.</given-names></name> <name><surname>Hayashi</surname> <given-names>N.</given-names></name> <name><surname>Maeda</surname> <given-names>K.</given-names></name> <name><surname>Ito</surname> <given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title><italic>Perilla frutescens</italic> extract ameliorates DSS-induced colitis by suppressing proinflammatory cytokines and inducing anti-inflammatory cytokines.</article-title> <source><italic>Am. J. Physiol. Gastrointest. Liver Physiol.</italic></source> <volume>308</volume> <fpage>G32</fpage>&#x2013;<lpage>G41</lpage>. <pub-id pub-id-type="doi">10.1152/ajpgi.00294.2014</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>D.</given-names></name> <name><surname>Dubois</surname> <given-names>R. N.</given-names></name></person-group> (<year>2010</year>). <article-title>The role of COX-2 in intestinal inflammation and colorectal cancer.</article-title> <source><italic>Oncogene</italic></source> <volume>29</volume> <fpage>781</fpage>&#x2013;<lpage>788</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2009.421</pub-id></citation></ref>
<ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>F.</given-names></name> <name><surname>Wang</surname> <given-names>C.</given-names></name> <name><surname>Liu</surname> <given-names>S.</given-names></name> <name><surname>Wang</surname> <given-names>H.</given-names></name> <name><surname>Xi</surname> <given-names>S.</given-names></name> <name><surname>Sun</surname> <given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>Inflammatory cytokine COX-2 mediated cell proliferation through increasing cyclin D1 expression induced by inorganic arsenic in SV-HUC-1 human uroepithelial cells.</article-title> <source><italic>Toxicol. Res.</italic></source> <volume>4</volume> <fpage>1400</fpage>&#x2013;<lpage>1408</lpage>. <pub-id pub-id-type="doi">10.1039/C5TX00196J</pub-id></citation></ref>
<ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wesolowski</surname> <given-names>R.</given-names></name> <name><surname>Markowitz</surname> <given-names>J.</given-names></name> <name><surname>Carson</surname> <given-names>W. E.</given-names> <suffix>III.</suffix></name></person-group> (<year>2013</year>). <article-title>Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.</article-title> <source><italic>J. Immunother. Cancer</italic></source> <volume>1</volume>:<issue>10</issue>. <pub-id pub-id-type="doi">10.1186/2051-1426-1-10</pub-id></citation></ref>
<ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wirtz</surname> <given-names>S.</given-names></name> <name><surname>Neufert</surname> <given-names>C.</given-names></name> <name><surname>Weigmann</surname> <given-names>B.</given-names></name> <name><surname>Neurath</surname> <given-names>M. F.</given-names></name></person-group> (<year>2007</year>). <article-title>Chemically induced mouse models of intestinal inflammation.</article-title> <source><italic>Nat. Protoc.</italic></source> <volume>2</volume> <fpage>541</fpage>&#x2013;<lpage>546</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2007.41</pub-id></citation></ref>
<ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Witzel</surname> <given-names>I. I.</given-names></name> <name><surname>Koh</surname> <given-names>L. F.</given-names></name> <name><surname>Perkins</surname> <given-names>N. D.</given-names></name></person-group> (<year>2010</year>). <article-title>Regulation of cyclin D1 gene expression.</article-title> <source><italic>Biochem. Soc. Trans.</italic></source> <volume>38(Pt 1)</volume> <fpage>217</fpage>&#x2013;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1042/BST0380217</pub-id></citation></ref>
<ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname> <given-names>Z.</given-names></name> <name><surname>Gauldie</surname> <given-names>J.</given-names></name> <name><surname>Cox</surname> <given-names>G.</given-names></name> <name><surname>Baumann</surname> <given-names>H.</given-names></name> <name><surname>Jordana</surname> <given-names>M.</given-names></name> <name><surname>Lei</surname> <given-names>X. F.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses.</article-title> <source><italic>J. Clin. Invest.</italic></source> <volume>101</volume> <fpage>311</fpage>&#x2013;<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1172/JCI1368</pub-id></citation></ref>
<ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname> <given-names>P.</given-names></name> <name><surname>Turkson</surname> <given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Targeting STAT3 in cancer: how successful are we?</article-title> <source><italic>Expert Opin. Investig. Drugs</italic></source> <volume>18</volume> <fpage>45</fpage>&#x2013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1517/13543780802565791</pub-id></citation></ref>
<ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>J.</given-names></name> <name><surname>Dou</surname> <given-names>W.</given-names></name> <name><surname>Zhang</surname> <given-names>E.</given-names></name> <name><surname>Sun</surname> <given-names>A.</given-names></name> <name><surname>Ding</surname> <given-names>L.</given-names></name> <name><surname>Wei</surname> <given-names>X.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway.</article-title> <source><italic>Am. J. Physiol. Gastrointest. Liver Physiol.</italic></source> <volume>306</volume> <fpage>G27</fpage>&#x2013;<lpage>G36</lpage>. <pub-id pub-id-type="doi">10.1152/ajpgi.00465.2012</pub-id></citation></ref>
<ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>X. J.</given-names></name> <name><surname>Yan</surname> <given-names>L. L.</given-names></name> <name><surname>Yin</surname> <given-names>P. P.</given-names></name> <name><surname>Shi</surname> <given-names>L. L.</given-names></name> <name><surname>Zhang</surname> <given-names>J. H.</given-names></name> <name><surname>Liu</surname> <given-names>Y. J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Structural characterisation and antioxidant activity evaluation of phenolic compounds from cold-pressed <italic>Perilla frutescens</italic> var. <italic>arguta</italic> seed flour.</article-title> <source><italic>Food Chem.</italic></source> <volume>164</volume> <fpage>150</fpage>&#x2013;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1016/j.foodchem.2014.05.062</pub-id></citation></ref>
</ref-list>
</back>
</article>